Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 281


Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018.

Vellas B, Bain LJ, Touchon J, Aisen PS.

J Prev Alzheimers Dis. 2019;6(3):198-203. doi: 10.14283/jpad.2019.11.


Editorial: Failure After Failure. What Next in AD Drug Development?

Aisen PS.

J Prev Alzheimers Dis. 2019;6(3):150. doi: 10.14283/jpad.2019.23. No abstract available.


Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.

Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D.

N Engl J Med. 2019 Apr 11;380(15):1408-1420. doi: 10.1056/NEJMoa1812840.


A randomized clinical trial to evaluate home-based assessment of people over 75 years old.

Sano M, Zhu CW, Kaye J, Mundt JC, Hayes TL, Ferris S, Thomas RG, Sun CK, Jiang Y, Donohue MC, Schneider LS, Egelko S, Aisen PS, Feldman HH; Alzheimer Disease Cooperative Study Investigators.

Alzheimers Dement. 2019 May;15(5):615-624. doi: 10.1016/j.jalz.2019.01.007. Epub 2019 Mar 11.


Unsuccessful trials of therapies for Alzheimer's disease.

Schott JM, Aisen PS, Cummings JL, Howard RJ, Fox NC.

Lancet. 2019 Jan 5;393(10166):29. doi: 10.1016/S0140-6736(18)31896-8. No abstract available.


Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention.

Rafii MS, Aisen PS.

CNS Drugs. 2019 Feb;33(2):99-106. doi: 10.1007/s40263-018-0598-1.


Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability.

Hurtz S, Chow N, Watson AE, Somme JH, Goukasian N, Hwang KS, Morra J, Elashoff D, Gao S, Petersen RC, Aisen PS, Thompson PM, Apostolova LG.

Neuroimage Clin. 2019;21:101574. doi: 10.1016/j.nicl.2018.10.012. Epub 2018 Oct 14.


Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative.

Li D, Iddi S, Thompson WK, Rafii MS, Aisen PS, Donohue MC.

Alzheimers Dement (Amst). 2018 Aug 29;10:657-668. doi: 10.1016/j.dadm.2018.07.008. eCollection 2018.


Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.

Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2019 Jan;15(1):106-152. doi: 10.1016/j.jalz.2018.08.005. Epub 2018 Oct 13. Review.


Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial.

Sano M, Egelko S, Zhu CW, Li C, Donohue MC, Ferris S, Kaye J, Mundt JC, Sun CK, Aisen PS, Feldman HH.

Alzheimers Dement. 2018 Nov;14(11):1397-1405. doi: 10.1016/j.jalz.2018.05.016. Epub 2018 Oct 5.


Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline?

Coley N, Raman R, Donohue MC, Aisen PS, Vellas B, Andrieu S.

J Nutr Health Aging. 2018;22(8):982-998. doi: /10.1007/s12603-018-1052-2.


Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative.

Iddi S, Li D, Aisen PS, Rafii MS, Litvan I, Thompson WK, Donohue MC.

Neurodegener Dis. 2018;18(4):173-190. doi: 10.1159/000488780. Epub 2018 Aug 8.


What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force.

Aisen PS, Siemers E, Michelson D, Salloway S, Sampaio C, Carrillo MC, Sperling R, Doody R, Scheltens P, Bateman R, Weiner M, Vellas B.

J Prev Alzheimers Dis. 2018;5(3):171-174. doi: 10.14283/jpad.2018.23.


Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.

Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, Senda M, Ito K, Ikeuchi T, Kuwano R, Matsuda H; Japanese Alzheimer's Disease Neuroimaging Initiative, Sun CK, Beckett LA, Petersen RC, Weiner MW, Aisen PS, Donohue MC; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2018 Aug;14(8):1077-1087. doi: 10.1016/j.jalz.2018.03.009. Epub 2018 May 9.


Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.

Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D.

N Engl J Med. 2018 May 3;378(18):1691-1703. doi: 10.1056/NEJMoa1706441.


Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial.

Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA, Siffert J, Aisen PS; AAV2-NGF Study Team.

JAMA Neurol. 2018 Jul 1;75(7):834-841. doi: 10.1001/jamaneurol.2018.0233.


Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease.

Liu-Seifert H, Case MG, Andersen SW, Holdridge KC, Aisen PS, Kollack-Walker S, Siemers E.

J Prev Alzheimers Dis. 2018;5(1):8-14. doi: 10.14283/jpad.2018.1.


Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease.

Aisen PS.

Neurology. 2018 Jan 16;90(3):145. doi: 10.1212/WNL.0000000000004821. No abstract available.


Continuing Progress in Alzheimer's Disease Trials: Cause for Optimism.

Aisen PS.

J Prev Alzheimers Dis. 2017;4(4):211-212. doi: 10.14283/jpad.2017.34. No abstract available.


Elevated Brain Amyloid in Cognitively Normal Individuals-Reply.

Donohue MC, Aisen PS.

JAMA. 2017 Oct 10;318(14):1393-1394. doi: 10.1001/jama.2017.12962. No abstract available.


Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease.

Horgusluoglu-Moloch E, Nho K, Risacher SL, Kim S, Foroud T, Shaw LM, Trojanowski JQ, Aisen PS, Petersen RC, Jack CR Jr, Lovestone S, Simmons A, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative (ADNI).

Neurobiol Aging. 2017 Dec;60:92-103. doi: 10.1016/j.neurobiolaging.2017.08.010. Epub 2017 Aug 18.


On the path to 2025: understanding the Alzheimer's disease continuum.

Aisen PS, Cummings J, Jack CR Jr, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P, Dubois B.

Alzheimers Res Ther. 2017 Aug 9;9(1):60. doi: 10.1186/s13195-017-0283-5. Review.


Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary Report.

Weiner MW, Harvey D, Hayes J, Landau SM, Aisen PS, Petersen RC, Tosun D, Veitch DP, Jack CR Jr, Decarli C, Saykin AJ, Grafman J, Neylan TC; Department of Defense Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement (N Y). 2017 Jun;3(2):177-188. doi: 10.1016/j.trci.2017.02.005.


Cross-validation of optimized composites for preclinical Alzheimer's disease.

Donohue MC, Sun CK, Raman R, Insel PS, Aisen PS; AN-ADNI; AIBL; J-ADNI.

Alzheimers Dement (N Y). 2017 Jan;3(1):123-129. doi: 10.1016/j.trci.2016.12.001.


Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.

Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS; Alzheimer’s Disease Neuroimaging Initiative.

JAMA. 2017 Jun 13;317(22):2305-2316. doi: 10.1001/jama.2017.6669.


Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease.

Nho K, Kim S, Horgusluoglu E, Risacher SL, Shen L, Kim D, Lee S, Foroud T, Shaw LM, Trojanowski JQ, Aisen PS, Petersen RC, Jack CR Jr, Weiner MW, Green RC, Toga AW, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

BMC Med Genomics. 2017 May 24;10(Suppl 1):29. doi: 10.1186/s12920-017-0267-0.


Randomized controlled trials in mild cognitive impairment: Sources of variability.

Petersen RC, Thomas RG, Aisen PS, Mohs RC, Carrillo MC, Albert MS; Alzheimer's Disease Neuroimaging Initiative (ADNI) and Foundation for NIH (FNIH) Biomarkers Consortium AD MCI Placebo Data Analysis Project Team.

Neurology. 2017 May 2;88(18):1751-1758. doi: 10.1212/WNL.0000000000003907. Epub 2017 Apr 5.


A phase 3 trial of IV immunoglobulin for Alzheimer disease.

Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2017 May 2;88(18):1768-1775. doi: 10.1212/WNL.0000000000003904. Epub 2017 Apr 5.


Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2017 Apr;13(4):e1-e85. doi: 10.1016/j.jalz.2016.11.007. Epub 2017 Mar 22. Review.


Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.

Tosun D, Landau S, Aisen PS, Petersen RC, Mintun M, Jagust W, Weiner MW; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2017 May 1;140(5):1499-1512. doi: 10.1093/brain/awx046.


Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.

Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT, Chhatwal J, Marshall GA, Donovan N, Jackson J, Gatchel JR, Hanseeuw BJ, Schultz AP, Aisen PS, Johnson KA, Sperling RA.

Alzheimers Dement. 2017 Sep;13(9):1004-1012. doi: 10.1016/j.jalz.2017.01.018. Epub 2017 Feb 28.


Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease.

Moussa C, Hebron M, Huang X, Ahn J, Rissman RA, Aisen PS, Turner RS.

J Neuroinflammation. 2017 Jan 3;14(1):1. doi: 10.1186/s12974-016-0779-0.


The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Salazar J, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2017 May;13(5):561-571. doi: 10.1016/j.jalz.2016.10.006. Epub 2016 Dec 5. Review.


Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.

Sokolow S, Li X, Chen L, Taylor KD, Rotter JI, Rissman RA, Aisen PS, Apostolova LG.

J Alzheimers Dis. 2017;56(1):229-237. doi: 10.3233/JAD-160562.


Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment.

Insel PS, Donohue MC, Mackin RS, Aisen PS, Hansson O, Weiner MW, Mattsson N; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2016 Dec;48:172-181. doi: 10.1016/j.neurobiolaging.2016.08.017. Epub 2016 Aug 26.


Drug development in Alzheimer's disease: the path to 2025.

Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR Jr, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P.

Alzheimers Res Ther. 2016 Sep 20;8:39. doi: 10.1186/s13195-016-0207-9. Review.


Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease.

Nho K, Horgusluoglu E, Kim S, Risacher SL, Kim D, Foroud T, Aisen PS, Petersen RC, Jack CR Jr, Shaw LM, Trojanowski JQ, Weiner MW, Green RC, Toga AW, Saykin AJ; ADNI.

BMC Med Genomics. 2016 Aug 12;9 Suppl 1:30. doi: 10.1186/s12920-016-0190-9.


The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.

Yassine HN, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen PS, Chui HC, Schneider LS.

Alzheimers Res Ther. 2016 Jun 30;8:25. doi: 10.1186/s13195-016-0194-x.


Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial.

Sano M, Aisen PS, Andrews HF, Tsai WY, Lai F, Dalton AJ; International Down Syndrome and Alzheimer's Disease Consortium.

Neurology. 2016 May 31;86(22):2071-6. doi: 10.1212/WNL.0000000000002714. Epub 2016 May 4.


Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology.

Insel PS, Mattsson N, Mackin RS, Schöll M, Nosheny RL, Tosun D, Donohue MC, Aisen PS, Jagust WJ, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2016 May 17;86(20):1887-96. doi: 10.1212/WNL.0000000000002683. Epub 2016 Apr 15.


Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials.

Weninger S, Carrillo MC, Dunn B, Aisen PS, Bateman RJ, Kotz JD, Langbaum JB, Mills SL, Reiman EM, Sperling R, Santacruz AM, Tariot PN, Welsh-Bohmer KA.

Alzheimers Dement. 2016 May;12(5):631-2. doi: 10.1016/j.jalz.2016.04.001. No abstract available.


Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.

Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, Gao S, Boustani M, Crane PK, Petersen RC, Jack CR Jr, Jagust WJ, Aisen PS, Weiner MW, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2016 Jun 1;73(6):721-32. doi: 10.1001/jamaneurol.2016.0580.


A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS).

Wessels AM, Siemers ER, Yu P, Andersen SW, Holdridge KC, Sims JR, Sundell K, Stern Y, Rentz DM, Dubois B, Jones RW, Cummings J, Aisen PS.

J Prev Alzheimers Dis. 2015 Dec 1;2(4):227-241.


Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials.

Thomas RG, Albert M, Petersen RC, Aisen PS.

Alzheimers Dement. 2016 May;12(5):598-603. doi: 10.1016/j.jalz.2016.01.002. Epub 2016 Feb 23.


Cognitive/Clinical Endpoints for Pre-Dementia AD Trials.

Aisen PS.

J Prev Alzheimers Dis. 2015;2(2):82-84. No abstract available.


The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome.

Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen PS, Rissman RA.

Front Behav Neurosci. 2015 Sep 14;9:239. doi: 10.3389/fnbeh.2015.00239. eCollection 2015.


CAP--advancing the evaluation of preclinical Alzheimer disease treatments.

Reiman EM, Langbaum JB, Tariot PN, Lopera F, Bateman RJ, Morris JC, Sperling RA, Aisen PS, Roses AD, Welsh-Bohmer KA, Carrillo MC, Weninger S.

Nat Rev Neurol. 2016 Jan;12(1):56-61. doi: 10.1038/nrneurol.2015.177. Epub 2015 Sep 29. Review.


Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.

Lista S, Molinuevo JL, Cavedo E, Rami L, Amouyel P, Teipel SJ, Garaci F, Toschi N, Habert MO, Blennow K, Zetterberg H, O'Bryant SE, Johnson L, Galluzzi S, Bokde AL, Broich K, Herholz K, Bakardjian H, Dubois B, Jessen F, Carrillo MC, Aisen PS, Hampel H.

J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S171-91. doi: 10.3233/JAD-150202. Review.


A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease.

Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2015 Oct 20;85(16):1383-91. doi: 10.1212/WNL.0000000000002035. Epub 2015 Sep 11.


GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP.

Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC, Yoder KK, Hutchins GD, West JD, Tallman EF, Gao S, Foroud TM, Farlow MR, De Jager PL, Bennett DA, Aisen PS, Petersen RC, Jack CR Jr, Toga AW, Green RC, Jagust WJ, Weiner MW, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Brain. 2015 Oct;138(Pt 10):3076-88. doi: 10.1093/brain/awv231. Epub 2015 Aug 11.

Supplemental Content

Loading ...
Support Center